Moreover, BLM emerges as a regulator of the tumor immune microenvironment, inducing MHC-I expression in a manner dependent on ataxia-telangiectasia mutated/ataxia telangiectasia and Rad3-related–NF-κB (ATM/ATR–NF-κB) signaling. This evidence concerns the gene BLM and neoplasm.